A new independent 1876 page research with title ‘Melanoma – Pipeline Review, H2 2017‘ guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions and important players/vendors such as Advanced Cancer Therapeutics LLC,Aeglea BioTherapeutics Inc,Affichem SA etc. With n-number of tables and figures examining the Melanoma, the research gives you a visual, one-stop breakdown of the leading products, submarkets and market leader’s market revenue forecasts as well as analysis to 2022
Request a sample report @ https://www.htfmarketreport.com/sample-report/852552-melanoma-pipeline-review-1
The latest Pharmaceutical and Healthcare disease pipeline guide Melanoma – Pipeline Review, H2 2017, provides an overview of the Melanoma (Oncology) pipeline landscape.
Melanoma is a tumor that develops as a result of the malignant transformation of melanocytes. These cells are derived from the neural crest. Melanomas usually occur on the skin but can arise in other locations where neural crest cells migrate, such as in the gastrointestinal tract or brain. It is more common in women than in men. In women, the most common site is the legs and melanomas in men are most common on the back. Unusual moles, sores, lumps, blemishes, markings, or changes in the way an area of the skin looks or feels are sign of melanoma. Treatment includes surgery, radiation and proton therapy.
The Pharmaceutical and Healthcare latest pipeline guide Melanoma – Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Melanoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Melanoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Melanoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 17, 105, 122, 10, 209, 29 and 5 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, IND/CTA Filed, Preclinical and Discovery stages comprises 2, 16, 14, 1, 1, 69 and 12 molecules, respectively.
Melanoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from The proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
– The pipeline guide provides a snapshot of the global therapeutic landscape of Melanoma (Oncology).
– The pipeline guide reviews pipeline therapeutics for Melanoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
– The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
– The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
– The pipeline guide reviews key companies involved in Melanoma (Oncology) therapeutics and enlists all their major and minor projects.
– The pipeline guide evaluates Melanoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
– The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
– The pipeline guide reviews latest news related to pipeline therapeutics for Melanoma (Oncology)
Get customization & check discount for report @ https://www.htfmarketreport.com/request-discount/852552-melanoma-pipeline-review-1
Reasons to buy
– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Melanoma (Oncology).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Melanoma (Oncology) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Companies Mentioned in the Report: 4P-Pharma SAS,4SC AG,AB Science SA,AbbVie Inc,Abivax SA,Adaptimmune Therapeutics Plc,Aduro BioTech Inc,Advanced Cancer Therapeutics LLC,Aeglea BioTherapeutics Inc,Affichem SA,AGV Discovery SAS,AIMM Therapeutics BV,Alethia Biotherapeutics Inc,Alkermes Plc,Altor BioScience Corp,Amgen Inc,Anavex Life Sciences Corp,Angimmune LLC,Antibe Therapeutics Inc,Antigen Express Inc,APEIRON Biologics AG,Apexigen Inc,Aphios Corp,Aposense Ltd,Aptose Biosciences Inc,Arisaph Pharmaceuticals Inc,ARMO Biosciences Inc,Array BioPharma Inc,Asana BioSciences LLC,Astex Pharmaceuticals Inc,AstraZeneca Plc,Aurigene Discovery Technologies Ltd,Basilea Pharmaceutica Ltd,Batu Biologics Inc,Bayer AG,BeiGene Ltd,Beijing Kawin Technology Share-Holding Co Ltd,Bellicum Pharmaceuticals Inc,BerGenBio ASA,Bio-Cancer Treatment International Ltd,Biocad,Biogazelle NV,Biohaven Pharmaceutical Holding Company Ltd,BioLineRx Ltd,Bionomics Ltd,BioNTech AG,Biothera Pharmaceutical Inc,Biovista Inc,Boehringer Ingelheim GmbH,Boston Biomedical Inc,BrightPath Biotherapeutics Co Ltd,Bristol-Myers Squibb Co,Calithera Biosciences Inc,Can-Fite BioPharma Ltd,CBT Pharmaceuticals Inc,CCRP Therapeutics GmbH,Celgene Corp,Celldex Therapeutics Inc,Celprogen Inc,Celyad SA,Checkmate Pharmaceuticals Inc,Checkpoint Therapeutics Inc,Chipscreen Biosciences Ltd,Chugai Pharmaceutical Co Ltd,Cipher Pharmaceuticals Inc,Corvus Pharmaceuticals Inc,Curevac AG,CytomX Therapeutics Inc,Cytori Therapeutics Inc,CytoVac AS,Cytune Pharma SAS,CyTuVax BV,CZ BioMed Corp,Daiichi Sankyo Co Ltd,Deciphera Pharmaceuticals LLC,DEKK-TEC Inc,Dynavax Technologies Corp,Eisai Co Ltd,Eli Lilly and Co,Elsalys Biotech SAS,Ensol Biosciences Inc,EntreChem SL,eTheRNA Immunotherapies NV,Exelixis Inc,Exicure Inc,F. Hoffmann-La Roche Ltd,Faron Pharmaceuticals Oy,Fountain Biopharma Inc,Galapagos NV,Galectin Therapeutics Inc,Genelux Corp,Genentech Inc,Genmab A/S,Genocea Biosciences Inc,Genzyme Corp,GlaxoSmithKline Plc,GTx Inc,Hanmi Pharmaceuticals Co Ltd,Heat Biologics Inc,Hemispherx Biopharma Inc,Histogen Inc,HitGen LTD,Horizon Pharma Plc,Humanigen Inc,Humorigin Biotechnology Corp,Idera Pharmaceuticals Inc,Ignyta Inc,Immodulon Therapeutics Ltd,Immune Design Corp,Immune Response BioPharma Inc,ImmunGene Inc,Immunocore Ltd,ImmunoGen Inc,Immunomedics Inc,Immutep Ltd,IMPACT Therapeutics Inc,Imugene Ltd,Incyte Corp,Infinity Pharmaceuticals Inc,Innovation Pharmaceuticals Inc,Inovio Pharmaceuticals Inc,InteRNA Technologies BV,IO Biotech ApS,Iovance Biotherapeutics Inc,JHL Biotech Inc,Jiangsu Hengrui Medicine Co Ltd,Johnson & Johnson,Jounce Therapeutics Inc,K-Stemcell Co Ltd,Karus Therapeutics Ltd,Karyopharm Therapeutics Inc,Kite Pharma Inc,Kringle Pharma Inc,Leap Therapeutics Inc,Lentigen Technology Inc,Lipotek Pty Ltd,Lixte Biotechnology Holdings Inc,Loxo Oncology Inc,Lupin Ltd,Lytix Biopharma AS,MabVax Therapeutics Holdings Inc,MacroGenics Inc,Madrigal Pharmaceuticals Inc.,Magnus Life Ltd,MaxiVAX SA,MediaPharma SRL,Medicenna Therapeutics Corp,MedImmune LLC,MELEMA Pharma GmbH,Merck & Co Inc,Merck KGaA,Millennium Pharmaceuticals Inc,Moderna Therapeutics Inc,Molecular Templates Inc,Moleculin Biotech Inc,Morphotek Inc,NanoVector Inc,NantKwest Inc,Nektar Therapeutics,Neonc Technologies Inc,Nerviano Medical Sciences Srl,NewLink Genetics Corp,NormOxys Inc,Northwest Biotherapeutics Inc,Novartis AG,Omeros Corp,Oncology Research International Ltd,Oncolys BioPharma Inc,OncoNOx ApS,OncoSec Medical Inc,OncoTartis Inc,Oncovir Inc,Ono Pharmaceutical Co Ltd,Opsona Therapeutics Ltd,Orega Biotech SAS,OSE Immunotherapeutics,Pacific Northwest Biotechnology LLC,Patrys Ltd,PCI Biotech Holding ASA,PepVax Inc,Pfizer Inc,Pharmicell Co Ltd,Philogen SpA,PinCell srl,Pivotal BioSciences Inc,Plexxikon Inc,Polaris Pharmaceuticals Inc,Polyplus-Transfection SA,Primevax Immuno Oncology Inc,Propanac Biopharma Inc,Provectus Biopharmaceuticals Inc,Provenance Biopharmaceuticals Corp,Qu Biologics Inc,Rafael Pharmaceuticals Inc,Reata Pharmaceuticals Inc,Recombio SL,Redx Pharma Plc,Regeneron Pharmaceuticals Inc,Rexahn Pharmaceuticals Inc,Rgenix Inc,Rubicon Biotechnology Inc,RXi Pharmaceuticals Corp,Sanofi,SATT North SAS,Scancell Holdings Plc,SilaGene Inc,Sillajen Biotherapeutics,Sino Biopharmaceutical Ltd,SolaranRx Inc,Sorrento Therapeutics Inc,Spotlight Innovation Inc,Sumitomo Dainippon Pharma Co Ltd,Sun Pharma Advanced Research Company Ltd,Susavion Biosciences Inc,SuviCa Inc,Syndax Pharmaceuticals Inc,Synthon Holdings BV,Syntrix Biosystems Inc,Tactiva Therapeutics LLC,Taiga Biotechnologies Inc,Taiwan Liposome Company Ltd,Takara Bio Inc,Takeda Pharmaceutical Co Ltd,Takis Srl,Targovax ASA,TC BioPharm Ltd,Theravectys SA,Tikcro Technologies Ltd,TILT Biotherapeutics Ltd,Tiltan Pharma Ltd,Tocagen Inc,TREAT U SA,TVAX Biomedical Inc,UbiVac LLC,Ultimovacs AS,UNC Health Care,Unleash Immuno Oncolytics Inc,Vaccibody AS,Vascular Biogenics Ltd,Vault Pharma Inc,Vaxenta Biotechnologies,Vichem Chemie Research Ltd,ViiV Healthcare UK Ltd,Viralytics Ltd,ViraTherapeutics GmbH,VLP Therapeutics LLC,WntResearch AB,X4 Pharmaceuticals Inc,Zestagen SA
Buy this report @ https://www.htfmarketreport.com/buy-now?format=1&report=852552
Table of Contents
Table of Contents 2
Melanoma – Overview 12
Melanoma – Therapeutics Development 13
Melanoma – Therapeutics Assessment 72
Melanoma – Companies Involved in Therapeutics Development 105
Melanoma – Drug Profiles 214
Melanoma – Dormant Projects 1774
Melanoma – Discontinued Products 1801
Melanoma – Product Development Milestones 1805
Appendix 1817List of Tables
Number of Products under Development for Melanoma, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..3), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..4), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..5), H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..6), H2 2017
Number of Products under Development by Companies, H2 ….Continued
View Detailed Table of Content @ https://www.htfmarketreport.com/reports/852552-melanoma-pipeline-review-1
Thanks for reading this article, you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.
CRAIG FRANCIS (PR & Marketing Manager)
Ph: +1 (206) 317 1218